Eased Tensions On Korean Peninsula To Fuel Botanical Drug R&D?
Executive Summary
Herbal-derived drug development on the Korean peninsula is poised to get an initial boost once the relationship between the North and South improves, although it is uncertain how the possible easing of tensions between the two countries will broadly affect South Korea's pharma sector.
You may also be interested in...
Kaesong Complex A Starting Point For Two Koreas' Healthcare Cooperation?
As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests.
Dong-A Ties With NeuroBo For Diabetic Neuropathy, Alzheimer's
Dong-A makes notable progress in botanical drug programs, reaching deals for its diabetic neuropathic pain and Alzheimer's disease drug assets with Boston-based NeuroBo Pharmaceuticals.
Korea Q2 Roundup: In-House Drugs, Exports Help Hanmi, Daewoong, Boryung
Among the strong performers, Hanmi benefitted from growth for in-house-developed metabolic disease drugs and China cold syrup sales and Daewoong was boosted by exports of botulinum toxin, while Boryung reported record quarterly sales helped by its flagship antihypertensive.